Home » Stocks » Celldex Therapeutics

Celldex Therapeutics, Inc. (CLDX)

Stock Price: $11.14 USD -0.57 (-4.87%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $11.50 +0.36 (3.23%) Aug 7, 6:47 PM

Stock Price Chart

Key Info

Market Cap 435.87M
Revenue (ttm) 4.88M
Net Income (ttm) -45.52M
Shares Out 38.83M
EPS (ttm) -2.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $11.14
Previous Close $11.71
Change ($) -0.57
Change (%) -4.87%
Day's Open 11.30
Day's Range 10.50 - 12.16
Day's Volume 516,615
52-Week Range 1.50 - 13.91

More Stats

Market Cap 435.87M
Enterprise Value 231.99M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.83M
Float 15.47M
EPS (basic) -2.57
EPS (diluted) -2.93
FCF / Share -2.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.53M
Short Ratio 0.43
Short % of Float 2.45%
Beta 3.30
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 89.39
PB Ratio 5.36
Revenue 4.88M
Operating Income -55.76M
Net Income -45.52M
Free Cash Flow -46.86M
Net Cash 203.88M
Net Cash / Share 5.21
Gross Margin -801.87%
Operating Margin -1,143.54%
Profit Margin -1,035.20%
FCF Margin -961.12%
ROA -25.25%
ROE -47.11%
ROIC -63.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$17.00*
(52.60% upside)
Low
16.0
Current: $11.14
High
18.0
Target: 17.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.579.5412.746.795.483.594.1111.209.2746.79
Revenue Growth-62.54%-25.15%87.78%23.83%52.82%-12.77%-63.3%20.91%-80.2%-
Gross Profit3.579.5412.746.795.483.591.780.430.1534.72
Operating Income-56.33-186-122-133-130-122-81.44-58.08-43.40-6.46
Net Income-50.88-151-93.03-129-127-118-81.55-59.12-44.80-2.53
Shares Outstanding14.5110.448.576.776.475.965.323.852.632.12
Earnings Per Share-3.51-14.48-10.86-18.99-19.65-19.80-15.30-15.30-16.95-1.20
Operating Cash Flow-46.42-75.24-99.93-113-98.89-102-67.67-49.78-35.66-30.37
Capital Expenditures-0.73-0.81-1.79-2.75-4.88-1.93-4.22-0.30-0.51-2.10
Free Cash Flow-47.15-76.05-102-116-104-103-71.89-50.09-36.17-32.47
Cash & Equivalents64.3894.0213919029020130383.9653.3161.10
Total Debt3.66------11.3415.1422.41
Net Cash / Debt60.7394.0213919029020130372.6238.1738.69
Assets12315631638333824834712697.99110
Liabilities28.9131.7579.2611847.4836.3527.3029.7729.2734.69
Book Value94.0312423626529021232095.7768.7275.26
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Celldex Therapeutics, Inc.
Country United States
Employees 127
CEO Anthony S. Marucci

Stock Information

Ticker Symbol CLDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CLDX
IPO Date March 10, 2008

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of immunotherapies and other cancer-targeting biologics. It develops CDX-1140, an agonist human monoclonal antibody, which is being studied as a single-agent and in combination with CDX-301 in a Phase I dose-escalation study in metastatic solid tumors and B cell lymphomas; CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 that is in an early Phase II study in advanced head and neck squamous cell cancer in combination with Erbitux; CDX-0159, a Phase I monoclonal antibody that binds the KIT receptor and inhibits its activity; and CDX-527, a bispecific antibody that uses anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway. The company also holds exclusive rights to CDX-301 and CD40 ligand, which are immune modulating molecules that increase the numbers and activity of immune cells that control immune responses. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton; Amgen Inc.; Yale University; and MedImmune, LLC. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.